Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sensei and our pioneering lead program, solnerstotug.
- 01/08/2025
|
Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
- BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi's 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.
- 11/27/2024
|
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors.
- 11/14/2024
|
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
- BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.
- 10/29/2024
|
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
- BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
- 09/04/2024
|
Sensei Biotherapeutics to Present at Upcoming Conferences
- BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:
- 09/04/2024
|
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. “Collectively, the clinical data presented on SNS-101 over the past six months demonstrated early signs of clinical activity in a patient population generally resistant to immunotherapy, a well-tolerated safety profile, and the avoidance of a pharmacokinetic sink that hindered first-generation approaches to targeting VISTA,” said John Celebi, President and Chief Executive Officer.
- 08/06/2024
|
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
- BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.
- 05/30/2024
|
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
- Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA.
- 05/24/2024
|
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
- - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
- 05/23/2024
|
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
- PARIS--(BUSINESS WIRE)--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company.
- 05/10/2024
|
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates. “Building upon our initial data for SNS-101, which we believe support a favorable and potentially best-in-class clinical safety and PK profile, we now look forward to sharing topline dose escalation data at ASCO in June and initial dose expansion data in the fourth quarter of this year,” said John Celebi, President and Chief Executive Officer.
- 05/09/2024
|
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
- BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
- 04/24/2024
|
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
- BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets' at Canaccord Genuity's Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.
- 04/09/2024
|
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
- BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
- 04/04/2024
|
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
- BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development' at the 3rd Annual VISTA Symposium. The VISTA Symposium will convene scientific experts and industry leaders to explore the important emerging role of VISTA in cancer immunotherapy and will review the latest insights on VISTA biology, the growing potential of VISTA as a therapeutic target in multiple cancer indications and share updates on the ongoing clinical development of anti-VISTA therapies. The symposium will take place virtually on Wednesday, March 27 from 11 a.m. to 3:30 p.m. ET.
- 03/22/2024
|
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
- BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
- 03/06/2024
|
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- - Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -
- 02/28/2024
|
Sensei Biotherapeutics to Present at Upcoming Conferences
- BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:
- 02/07/2024
|
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- - Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance sheet with cash runway extended into the fourth quarter of 2025 - BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones. “In 2023, we significantly advanced our lead clinical asset while prudently maintaining our strong balance sheet,” said John Celebi, President and Chief Executive Officer.
- 01/04/2024
|
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- - SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported -
- 11/07/2023
|
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- - Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts -
- 11/03/2023
|
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
- BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
- 11/01/2023
|
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
- BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
- 10/25/2023
|
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
- BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the European Society for Medical Oncology Congress (ESMO) 2023.
- 10/23/2023
|
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®
- - Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety data expected in the fourth quarter of 2023 and topline monotherapy data expected in 2024 - - New guidance for initial combination PK and safety data expected in the first quarter of 2024, with preliminary anti-tumor activity data expected in 2024 - BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
- 09/27/2023
|
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- - New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile -
- 09/21/2023
|
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy. The new data build on SNS-101's preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. SNS-101 is currently in a Phase 1/2 clinical study .
- 09/13/2023
|
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
- BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in the following investor conferences in September 2023:
- 08/30/2023
|
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-blocking antibody for the treatment of advanced solid tumors
- 08/03/2023
|
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
- BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors' at Canaccord Genuity's Horizons in Oncology Virtual Conference on Thursday, April 20th at 3:00 p.m. ET.
- 04/13/2023
|
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
- BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL.
- 03/14/2023
|
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
- BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia, being held February 19-22, 2023 in Banff, Alberta, Canada. The presentation will be made by Sensei's Chief Scientific Officer, Dr. Edward van der Horst.
- 02/14/2023
|
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
- BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.
- 11/02/2022
|
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022.
- 10/05/2022
|
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
- BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – October 1, 2022 at the New York Hilton Midtown in New York, New York.
- 09/21/2022
|
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
- BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022:
- 08/23/2022
|
Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February
- Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?
- 02/21/2022
|
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 - 14, 2021. These data are the first preclinical data to be presented by Sensei Bio in a scientific forum from the company's TMAb (Tumor Microenvironment Activated biologics) platform.
- 10/01/2021
|
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
- - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model –
- 08/04/2021
|
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
- BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Kristian Humer, former managing director of Banking, Capital Markets & Advisory for the Global Healthcare team at Citigroup, Inc. as an independent director to the company's board of directors, effective July 30, 2021.
- 08/02/2021
|
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
- You might not have heard of them, but one went up big while the other served up a massive disappointment.
- 06/29/2021
|
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
- - Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs -
- 06/28/2021
|
5 Stocks With High Guru and Insider Buys in the Past 3 Months
- According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial), Sensei Biotherapeutics Inc. ( SNSE , Financial), Hayward Holdings Inc. ( HAYW , Financial), Vistra Corp. ( VST , Financial) and Peloton Interactive Inc. ( PTON , Financial).
- 06/09/2021
|
Sensei Biotherapeutics (SNSE) Stock: 30.11% Increase Explanation
- The stock price of Sensei Biotherapeutics Inc (NASDAQ: SNSE) increased by 30.11% today. This is why it happened.
- 05/20/2021
|
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
- – Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –
- 05/19/2021
|
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
- - ImmunoPhage™ platform programs and the VISTA program continue to advance -
- 05/12/2021
|
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D.
- BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D., Professor of Medicine, Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and Richard Ulevitch, Ph.D., Professor of Immunology and Chairman Emeritus at The Scripps Research Institute, to its Immuno-Oncology Advisory Board.
- 05/05/2021
|
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D.
- Entrepreneurial leader brings expertise growing biotech platform companies Entrepreneurial leader brings expertise growing biotech platform companies
- 04/05/2021
|
7 Stocks With Significant Insider Buying
- There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.
- 03/09/2021
|
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
- BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present at the Oppenheimer 31st Annual Virtual Healthcare Conference on Tuesday, March 16th, 2021 at 9:20 a.m. ET.
- 03/09/2021
|
7 Beaten Down Stocks With Significant Insider Buying
- If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.
- 03/01/2021
|
Insider Weekends: Sell/Buy Ratio Spikes Well Over 100
- Insider Weekends: Sell/Buy Ratio Spikes Well Over 100
- 02/28/2021
|
Sensei Biotherapeutics Announces Closing of Initial Public Offering
- BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of its common stock on February 8, 2021, as well as the issuance of an additional 1,030,243 shares pursuant to the exercise by the underwriters of their option to purchase additional shares on February 10, 2021, at a public offering price of $19.00 per share. The gross proceeds to Sensei from the two closings, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, were approximately $152.6 million. All of the shares in the offering were offered by Sensei. Sensei's common stock is listed on the Nasdaq Global Market under the ticker symbol “SNSE.”
- 02/10/2021
|
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
- The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.
- 02/08/2021
|
A Busy Day for Biotech IPOs
- Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here's how they fared.
- 02/04/2021
|
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
- BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol “SNSE.” In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on February 8, 2021 subject to the satisfaction of customary closing conditions.
- 02/03/2021
|
